Cargando…

Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness

BACKGROUND: Treatment with tumor-Infiltrating Lymphocytes (TIL) is an innovative therapy for advanced melanoma with promising clinical phase I/II study results and likely beneficial cost-effectiveness. As a randomized controlled trial on the effectiveness of TIL therapy in advanced melanoma compared...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lindenberg, Melanie, Retèl, Valesca, Rohaan, Maartje, van den Berg, Joost, Haanen, John, van Harten, Wim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393723/ https://www.ncbi.nlm.nih.gov/pubmed/32736535 http://dx.doi.org/10.1186/s12885-020-07166-9

Ejemplares similares

Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation
por: Retèl, Valesca P., et al.
Publicado: (2018)

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product
por: Lindenberg, Melanie A., et al.
Publicado: (2018)

Image-guided navigation for locally advanced primary and locally recurrent rectal cancer: evaluation of its early cost-effectiveness
por: Lindenberg, Melanie, et al.
Publicado: (2022)

Early budget impact analysis on magnetic seed localization for non-palpable breast cancer surgery
por: Lindenberg, Melanie, et al.
Publicado: (2020)

Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option
por: Rohaan, Maartje W., et al.
Publicado: (2018)

Cost-utility analysis on robot-assisted and laparoscopic prostatectomy based on long-term functional outcomes
por: Lindenberg, Melanie A., et al.
Publicado: (2022)

Scenario drafting to anticipate future developments in technology assessment
por: Retèl, Valesca P, et al.
Publicado: (2012)

Understanding the Costs of Surgery: A Bottom-Up Cost Analysis of Both a Hybrid Operating Room and Conventional Operating Room
por: Patel, Sejal, et al.
Publicado: (2020)

Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis
por: van Amerongen, Rosa A, et al.
Publicado: (2016)

Adoptive cellular therapies: the current landscape
por: Rohaan, Maartje W., et al.
Publicado: (2018)

Whole genome sequencing in oncology: using scenario drafting to explore future developments
por: van de Ven, Michiel, et al.
Publicado: (2021)

Developing a dynamic simulation model to support the nationwide implementation of whole genome sequencing in lung cancer
por: van de Ven, Michiel, et al.
Publicado: (2022)

Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients
por: Miquel-Cases, Anna, et al.
Publicado: (2016)

Scenario drafting for early technology assessment of next generation sequencing in clinical oncology
por: Joosten, S.E.P., et al.
Publicado: (2016)

Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?
por: Byng, Danalyn, et al.
Publicado: (2021)

Cost-utility, cost-effectiveness, and budget impact of Internet-based cognitive behavioral therapy for breast cancer survivors with treatment-induced menopausal symptoms
por: Verbeek, Joost G. E., et al.
Publicado: (2019)

High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation
por: Verbeek, Joost G. E., et al.
Publicado: (2023)

Adoptive TIL in HPV-negative oral scca
por: Leidner, Rom, et al.
Publicado: (2015)

A cost-effectiveness analysis of a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy
por: Retèl, Valesca P, et al.
Publicado: (2011)

Affordable Prices Without Threatening the Oncological R&D Pipeline—An Economic Experiment on Transparency in Price Negotiations
por: Franzen, Nora, et al.
Publicado: (2022)

Innovations that reach the patient: early health technology assessment and improving the chances of coverage and implementation
por: van Harten, WH, et al.
Publicado: (2016)

TIL classified to memory state are correlated with response to immune checkpoint blockade
por: Jedema, Inge, et al.
Publicado: (2022)

Association between genomic recurrence risk and well-being among breast cancer patients
por: Retèl, Valesca P, et al.
Publicado: (2013)

Study protocol of a prospective multicenter study comparing (cost-)effectiveness of a tailored interdisciplinary head and neck rehabilitation program to usual supportive care for patients treated with concomitant chemo- or bioradiotherapy
por: Beck, Ann-Jean C. C., et al.
Publicado: (2019)

Cell-Free DNA at Diagnosis for Stage IV Non-Small Cell Lung Cancer: Costs, Time to Diagnosis and Clinical Relevance
por: Koole, Simone N., et al.
Publicado: (2022)

Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival
por: Khammari, Amir, et al.
Publicado: (2014)

Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers
por: Tas, Liselotte, et al.
Publicado: (2023)

Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology
por: van Harten, WH, et al.
Publicado: (2016)

Modulation of intracellular kinase signaling to improve TIL stemness and function for adoptive cell therapy
por: Feng, Hao, et al.
Publicado: (2022)

Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: Can disease-specific utilities be obtained?
por: Beck, Ann-Jean C. C., et al.
Publicado: (2019)

The Validity and Predictive Value of Blood-Based Biomarkers in Prediction of Response in the Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review
por: van Delft, Frederik, et al.
Publicado: (2020)

Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer
por: Simons, Martijn J. H. G., et al.
Publicado: (2021)

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
por: van den Berg, Joost H, et al.
Publicado: (2020)

TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients
por: Kvistborg, Pia, et al.
Publicado: (2012)

Fysikkpris til Fanamann
Publicado: (1981)

Petabytes til folket
Publicado: (2005)

Goldilocks and the three TILs
por: Dada, Hannah, et al.
Publicado: (2022)

Towards next‐generation TIL therapy: TILs enriched in neoepitope‐specific T cells
por: Arnaud, Marion, et al.
Publicado: (2023)

Preferences of Treatment Strategies among Women with Low-Risk DCIS and Oncologists
por: Byng, Danalyn, et al.
Publicado: (2021)

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial
por: Rohaan, Maartje W., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g0bpmhgod6ph3q8npdij71ekp5